Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments
“We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.
- “We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.
- “I’m thrilled to be joining the talented team at Aiolos Bio,” said Dr. Van der Merwe.
- We look forward to presenting and publishing data in 2024.” Dr. Van der Merwe will join Aiolos Bio effective January 2,2024.
- He joins Aiolos Bio from Bain Capital Life Sciences where he led and managed investments across therapeutic areas.